<DOC>
	<DOCNO>NCT02675660</DOCNO>
	<brief_summary>This study represent initial clinical evaluation oral formulation L-homoarginine . L-homoarginine L-arginine amino acid find food protein substrates nitric oxide synthase ( NOS ) . L-arginine available counter nutraceutical . This study provide information dose L-homoarginine order reach high physiological plasma concentration human .</brief_summary>
	<brief_title>Single Multiple Doses Oral Formulation L-Homoarginine Healthy Human Subjects</brief_title>
	<detailed_description>1 . Study Design In randomized , double-blind , placebo-controlled cross-over design participant receive either L-homoarginine 125 mg placebo daily morning four week . The study period separate washout phase four week , sequence medication randomly choose participant . The study precede run-in phase , participant receive single dose 125 mg L-homoarginine . Blood sample ( 2.7 ml ethylenediaminetetraacetic acid vacutainer ) plasma L-homoarginine determination draw time point 0 , 15 min , 30 min , 1 , 2 , 4 , 8 , 24 , 48 , 72 , 120 hour single multiple dos L-homoarginine placebo , respectively . At baseline four week supplementation period ( hArg placebo ) , routine laboratory , arginine , asymmetric dimethylarginine , pulse wave velocity , augmentation index , flow-mediated vasodilatation , transcranial magnetic stimulation , test battery attentional performance evaluate secondary endpoint . 2 . Study Duration One year 3 . Sample Size Calculation Statistical Evaluation Due exploratory nature pilot study , exploratory statistical method use statistical evaluation study result , formal sample size calculation perform . In previous study 20 participant include assess kinetic , dynamic , safety profile L-citrulline L-arginine [ Schwedhelm et al . 2007 ] . Statistical comparison perform use two-sided test , i.e . Student 's t-test ANOVA . A p &lt; 0.05 consider significant .</detailed_description>
	<criteria>1 . Male female , 2075 year age day dose generally healthy determine medical history , physical examination , laboratory test value 2 . For female , postmenopausal least 2 year prior screen ( confirm negative hormone panel , i.e. , plasma 17βestradiol concentration &lt; 20 pg/mL folliclestimulating hormone level &gt; 40 IU/mL ) contraception 3 . Has sign receive copy write informed consent form approve investigator 's Independent Ethics Committee ( IEC ) , understands purpose risk study agrees follow restriction schedule procedure define study protocol 1 . Sitting blood pressure great 160/100 less 90/60 mm Hg 2 . Sitting heart rate great 99 bpm less 50 beat per minute ( bpm ) 3 . History clinically significant hypotensive episode symptom faint , dizziness , lightheadedness 4 . Body Mass Index ( BMI ) great 32 less 16 screen [ BMI = Weight ( kg ) ÷ Height2 ( m2 ) ] 5 . History symptom cardiovascular disease , particularly coronary artery disease , arrhythmia , congestive heart failure 6 . History significant central nervous system disease , include transient ischemic attack , stroke , seizure disorder , behavioral disturbance</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>kinetic data</keyword>
	<keyword>volunteer</keyword>
</DOC>